Forty Seven, which is developing monoclonal antibodies for various cancers, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
The Menlo Park, CA-based company was founded in 2014 and booked n/a in sales for the 12 months ended March 31, 2018. It plans to list on the Nasdaq under the symbol FTSV. Forty Seven filed confidentially on March 23, 2018. Morgan Stanley and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.
